Top Markets
#1 Siacoin Siacoin +29.48%
#2 Official Trump Official Trump +25.53%
#3 Wrapped STX (Velar) Wrapped STX (Velar) +19.32%
#4 EXOD EXOD +18.93%
#5 MowCat MowCat +18.23%
#6 Unit Pump Unit Pump +16.28%
#7 Pump.fun Pump.fun +16.28%
#8 Melania Meme Melania Meme +15.60%
#9 Mubarak Mubarak +14.72%
#10 Wrapped POL Wrapped POL +13.16%
Coin of the day
Siacoin Siacoin
Settings
Language
ENGLISH
Currency
USD
Theme
Nymox Pharmaceutical Corporation Nymox Pharmaceutical Corporation

Nymox Pharmaceutical Corporation

NYMX
Rank in Stocks #23483
Nymox Pharmaceutical Corporation operates as a biopharmaceutical firm,... Nymox Pharmaceutical Corporation operates as a biopharmaceutical firm, primarily focused on the discovery and advancement of medications for the aging population across Canada, the United States, Europe, and other international regions. The company's leading experimental compound is Fexapotide Triflutate (NX-1207), which has successfully concluded Phase III clinical trials for benign prostatic hyperplasia treatment. It has also completed Phase II trials for localized low-grade prostate cancer and is currently in preclinical studies for hepatocellular carcinoma. In addition to its drug pipeline, Nymox develops and markets diagnostic products. These include NicAlert and TobacAlert, tests that utilize urine or saliva samples to identify the use of tobacco products. The company further offers AlzheimAlert, a proprietary urine-based assay designed to aid healthcare professionals in diagnosing Alzheimer's disease. Alongside this diagnostic tool, Nymox is actively researching and developing therapeutic treatments for Alzheimer's disease. Founded in 1989, the company is headquartered in Nassau, the Bahamas.
Share Price
$0.977
Last synced: 2023-08-11
Market Cap
$72.98M
Change (1 day)
4.94%
Change (1 year)
0.00%
Country
BS
Trade Nymox Pharmaceutical Corporation (NYMX)

Category

Healthcare
P/E ratio for Nymox Pharmaceutical Corporation (NYMX)
P/E ratio as of 2026 TTM: 0
According to Nymox Pharmaceutical Corporation latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 0. At the end of 2026 the company had a P/E ratio of 0.
P/E ratio history for Nymox Pharmaceutical Corporation from 2026 to 2026
P/E ratio at the end of each year
Year P/E Ratio Change
Not enough data for the provided dates.
P/E ratio for similar companies or competitors
Company P/E Ratio P/E Ratio Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 29.20 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 30.62 -
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 -7.93 -
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
 32.46 -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share.
A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.

Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.